• Home |
• Downloads |
• Glossary |
• Sitemap

Remuneration Report

• Introduction
• Remuneration Committee membership and meetings
• Remuneration Committee remit and key activities during the year
• AstraZeneca's overall remuneration policy and purpose
• Components of remuneration
• Executive Directors' and the Senior Executive Team's remuneration and terms of employment
• Audit
• Directors' emoluments in 2007
• Pensions
• Transactions with Directors
• Total shareholder return graphs
• Directors' interests in shares
• Share options
• Gains by Directors on exercise of share options

DIRECTORS’ REMUNERATION REPORT

“Our role in the Remuneration Committee is to provide governance and strategic oversight of remuneration on behalf of the Board. Our objective is to ensure that our compensation policies and practices support the generation of growth, and facilitate thereby the generation of value for shareholders. Meeting those objectives dominated our agenda during 2007. This included creating the appropriate compensation structures for the new MedImmune business.”

JOHN VARLEY
Chairman of the Remuneration Committee

This Directors’ Remuneration Report has been prepared in accordance with the Directors’ Remuneration Report Regulations 2002 (the Regulations) and meets the relevant requirements of the Financial Services Authority’s (FSA) Listing Rules. As required by the Regulations, a resolution to approve the report will be proposed at the Annual General Meeting (AGM) on Thursday 24 April 2008.

The following sections of the Directors’ Remuneration Report up to and including the section titled ‘Non-Executive Directors’ were not subject to audit by KPMG Audit Plc.